Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology

The deep and durable antitumor effects of antibody-based immunotherapies such as immune checkpoint inhibitors (ICIs) have revolutionized oncology and transformed the therapeutic landscape for many cancers. Several anti-programmed death receptor 1 and anti-programmed death receptor ligand 1 antibodie...

Full description

Bibliographic Details

Published in:	Clinical cancer research Vol. 26; no. 5; p. 984
Main Authors:	Autio, Karen A, Boni, Valentina, Humphrey, Rachel W, Naing, Aung
Format:	Journal Article
Language:	English
Published:	United States 01.03.2020
Subjects:	Animals Antibodies, Monoclonal - therapeutic use B7-H1 Antigen - antagonists & inhibitors CTLA-4 Antigen - antagonists & inhibitors Drug-Related Side Effects and Adverse Reactions - etiology Drug-Related Side Effects and Adverse Reactions - pathology Drug-Related Side Effects and Adverse Reactions - prevention & control Humans Immunotherapy - adverse effects Neoplasms - drug therapy Neoplasms - immunology Prodrugs - therapeutic use Programmed Cell Death 1 Receptor - antagonists & inhibitors
ISSN:	1557-3265, 1557-3265
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!